Objective: 1) To determine the efficacy of the powered endoscopic microdebrider as a tool in the management of obstructive laryngeal tumors. 2) To compare the histopathological diagnosis between a biopsy taken using the laryngeal forceps and the resected tissue from the microdebrider.
Results: All cases presented with moderate to severe stridor, the lesion obstructing more than 50% of the lumen of the larynx. In all cases tracheotomy could be avoided until a definitive therapy was initiated. No significant bleeding was encountered during these procedures. The operating time was directly dependent on the volume of the tumor. Both biopsies (one taken by forceps and the other from tissues resected by microdebrider) gave the same diagnosis except in 1 patient, as there were artifacts in microdebrider collected tissues.
Conclusion: Endoscopic debulking of laryngeal tumors using the microdebrider is a safe, accurate, and reliable method, thus preventing tracheotomy in most cases. The use of microdebrider does not preclude the submission of tissue for histological analysis. These preliminary results are encouraging and worthy of further evaluation and comparison with other techniques.
Laryngology/Broncho-Esophagology Murine Model of a Drug-Eluding Stent on Subglottic Stenosis
Jennifer Y. Lee, MD (presenter); Noam A. Cohen, MD, PhD; Sunil Singhal, MD; Kevin Leahy, MD, PhD; Ankona Ghosh, MD; Genevieve Philiponis; Natasha Mirza, MD Objective: The study investigates the effect of a localized, steroid-eluding stent on laryngotracheal complex (LTC) granulation in the murine model. We hypothesize that steroid treated LTCs will have reduced granulation compared to nontreated LTCs using 2 techniques.
Method: The established murine model of LTC stenosis was used to compare effects of local mometasone furoate on airway granulation tissue. Using H&E staining, the thickness of lamina propria between control and treatment LTCs were compared. Using real-time PCR, the relative level of IL1 and TGF beta were compared.
Results: Using microscopy and H&E staining, the LTCs were found to have decreased amounts of granulation after treatment with mometasone furoate compared to untreated LTCs. Using RT-PCR, the inflammatory marker IL-1 was significantly decreased in LTCs treated with the mometasone furoate stent compared to untreated mice.
Conclusion: Localized drug eluding stent appears to decrease granulation and inflammatory markers within laryngotracheal complexes. Further investigation into the therapeutic benefit of local drug-eluding stents in the airway is warranted.
Laryngology/Broncho-Esophagology
New Approaches for locally Advanced Nasopharyngeal Carcinoma Giancarlo Pecorari, MD (presenter); Luca Raimondo, MD; Massimiliano Garzaro, MD; Mario Airoldi; Giuseppe Riva, MD; Marta Cerutti, MD; Carlo Giordano, MD Objective: To evaluate 2 different schemes of neoadjuvant chemotherapy (NACT) followed by 2 different concomitant chemoradiotherapy (CHRT) schedules in loco-regionally advanced nasopharyngeal carcinoma (A-NPC) observed in a nonendemic population.
Method: Seventy homogeneous patients affected by A-NPC
were enrolled in this retrospective study. Forty patients (group A) underwent 3 cycles of NACT with cisplatin+epirubicin followed by cisplatin+70 Gy RT; and 30 patients (group B) received 3 cycles of NACT with carboplatin+taxol followed by weekly carboplatin+taxol for 7 weeks+concomitant 70Gy RT.
Results: After NACT, results in group A and B were: CRs 30% vs 33%, PRs 60% vs 60%, NC 10% vs 6.6%; after CHRT: CRs 75% vs 87%, PRs 25% vs 13%. After median follow-up of 54 months (A) and 49 months (B), 3-5 years progressionfree survival were 75% vs 80% and 65% vs 75%, respectively, and overall survival was 84% vs 85% and 77% vs 80%, respectively; 5 years locoregional control was 70% vs 90%, and 5 years distant metastases-free survival was 75% vs 85%. NACT toxicity was as follows: G3-4 neutropenia 40% vs 83%, G3 thrombocytopenia 12% vs 13%, G3 anemia 0% vs 10% and G3 mucositis 2.5% vs 6.6%; CHRT toxicity was as follows: G3-G4 neutropenia 20% vs 63%; G3 anemia 2.5% vs 17%, G3-G4 mucositis 32.5% vs 69%; skin toxicity 25% vs 23% and G3 neurotoxicity 5% vs 10%.
Conclusion: NACT followed by CHRT represents a feasible, highly effective treatment for patients with A-NPC, with excellent locoregional disease control and overall survival and with low incidence of distant metastases. Double drug CHRT in group B is characterized by higher incidence of acute toxicities without significant impact on major clinical outcomes.
